Bernstein Issues a Buy Rating on Centene (CNC)
Bernstein analyst Lance Wilkes assigned a Buy rating to Centene yesterday and set a price target of $48.00. The company’s shares closed yesterday at $35.40.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Wilkes is an analyst with an average return of -8.7% and a 32.67% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Cigna, Centene, and CVS Health.
Centene has an analyst consensus of Hold, with a price target consensus of $42.38.
Based on Centene’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.73 billion and a GAAP net loss of $1.1 billion. In comparison, last year the company earned a revenue of $40.81 billion and had a net profit of $283 million
Read More on CNC:
Disclaimer & DisclosureReport an Issue
- Closing Bell Movers: Health insurers rise on higher Medicare rate hike
- CMS finalizes 2027 Medicare Advantage payments with 2.48% increase
- Centene jumps 5% to $37.28 after CMS finalizes 2027 Medicare payments
- Centene put volume heavy and directionally bearish
- Trump Trade: U.S. strengthens tariffs on steel, aluminum, copper imports
